Merck’s trial of Keytruda regimen fails to meet primary endpoint
Merck & Co (MSD) has announced that its Phase III KEYNOTE-B21 (ENGOT-en11/GOG-3053) clinical trial of Keytruda plus chemotherapy in patients with newly diagnosed high-risk endometrial cancer following surgery with curative intent, failed to meet …